JW Therapeutics competitorsClear all

JW Therapeutics's top competitors include Neovii, Eutilex and Foghorn Therapeutics.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
JW Therapeutics
JW Therapeutics
JW Therapeutics is a biotech company focusing on clinical cell therapy technology.
Neovii
Neovii
Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
Eutilex
Eutilex
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology.
Foghorn Therapeutics
Foghorn Therapeutics
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
Founding Date
Founding Date
2016
Founding Date
2003
Founding Date
2015
Founding Date
2016
Type
Type
Private
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
CN HQ
Suzhou Shi, CN
Locations
Rapperswil-Jona, CH HQ
Gräfelfing, DE
Lexington, US
Locations
KR HQ
Locations
Cambridge, US HQ
Cambridge, US
Employees
Employees
784% decrease
Employees
86
Employees
108
Employees
85
Alexa Website Rank
Alexa Website Rank
262720
Alexa Website Rank
N/A
Alexa Website Rank
N/A
Alexa Website Rank
194154

Funding

Total funding raised
Total funding raised
$ 90m
Total funding raised
N/A
Total funding raised
$ 18.9m
Total funding raised
$ 50m
For sources of this data, please see the company profile

View company profiles

Neovii
HQ
Rapperswil-Jona, CH
Employees
86

Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.

View company
Eutilex
HQ
KR
Employees
108

Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology.

View company
Foghorn Therapeutics
HQ
Cambridge, US
Employees
85

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.

View company